ENHANCING THE EXPRESSION OF GENES IN MICROORGANISMS

Abstract: A bacterial cell is transformed with a gene encoding a desired product and with an enhancing DNA sequence cap­ able of enhancing the production of the desired product in the bacterial cell. The enhancing DNA sequence is capable of en­ hancing the production of an endogenous protease in a Gram-positive bacterial cell.

Description: This invention relates to enhancing the expression of genes in microorganisms. In its various aspects, it is concerned with transformed bacterial cells, methods for producing desired products involving the utilization of such cells, vectors comprising a DNA sequence capable of enhancing expression of genes and methods for isolating a DNA sequence for use in transforming the cells. In accordance with a first aspect of the invention we provide a vector comprising a Bacillus -derived enhancing DNA sequence capable of enhancing the production of a desired protease in a Bacillus cell, said vector being characterised in including first and second sequences, said second sequence being a Bacillus sequence which is not a portion of a sac Q sequence, said first sequence comprising a portion of a sac Q DNA sequence which when combined with said second sequence causes said enhancing, said first and second sequences together comprising less than the entire sac Q sequence. In preferred embodiments the vector is further characterised in that said first sequence comprises the sac Q sequence and in that said second sequence is adjacent and downstream from said first sequence and comprises the sequence In a second and alternative aspect thereof, the invention provides a method of making and isolating a DNA sequence capable of enhancing the production of a protease in a Bacillus strain other than a B. amyloliquefaciens strain, said method being characterized in comprising the steps of: (a) providing a cloning vector containing a portion of a Bacillus -derived sac Q DNA sequence, (b) digesting the DNA of a different Bacillus strain to give a plurality of DNA fragments, (c) inserting said fragments into said cloning vectors, (d) transforming bacteria of said bacterial strain with said cloning vectors, (e) assaying protease production in said transformed bacteria, (f) selecting bacteria exhibiting increased protease production, and (g) isolating said enhancing DNA sequence from said bacteria exhibiting increased protease production, said enhancing sequence comprising less than the entire sac Q sequence. The invention provides, in a third alternative aspect, a Bacillus cell characterized in that it is transformed with a gene encoding a desired product and with a Bacillus -derived enhancing DNA sequence capable of enhancing the production of said desired product in said Bacillus cell, in that said enhancing DNA sequence is capable of enhancing the production of an endogenous protease in a Bacillus cell, and in that said enhancing DNA sequence comprises a first and a second sequence, said second sequence being a Bacillus sequence which is not a portion of a sac Q sequence, said first sequence comprising a portion of a sac Q DNA sequence which, when combined with said second sequence causes said enhancing, said first and second sequences together comprising less than the entire sac Q sequence. In preferred embodiments, the Bacillus cell is a strain of Bacillus subtilis , B. licheniformis , B. acidocaldarius , B. polymyxa , B. stearothermophilus , B. thermoproteolyticus , B. coagulans , B. thuringiensis , B. megaterium , B. cereus , B. natto , or B. amyloliquefaciens ; and said second sequence is derived from or substantially identical to a DNA fragment of a Bacillus cell of a strain of any of Bacillus subtilis , B. licheniformis , B. acidocaldarius , B. polymyxa , B. stearothermophilus , B. thermoproteolyticus , B. coagulans , B. thuringiensis , B. megaterium , B. cereus , or B. natto ; the desired product is a protein, e.g., naturally-secreted prokaryotic protein such as a protease, an alkaline phosphatase, an amylase or another enzyme, or a eukaryotic protein or peptide such as an enzyme or a hormone; and the enhancing DNA sequence is carried on a multicopy plasmid and/or is integrated into the chromosome of the bacterial cell, which is most preferably of a B. subtilis strain. Because the enhancing sequences function by encoding protein products which enhance the production of the desired product, even greater enhancement of that product can be achieved by placing the enhancing sequence under the transcriptional control of a strong promoter to effect the production in the Bacillus cell of increased quantities of the protein product of the enhancing sequence. In a fourth alternative aspect of this invention, we provide a method for producing a desired product said method being characterized in comprising the steps of: (1) ligating a DNA sequence encoding said desired product to a DNA sequence including a regulatory DNA sequence which is substantially identical to a regulatory DNA sequence which regulates the expression of a DNA sequence which encodes a protease in a Bacillus species, preferably B. subtilis , to form a ligated DNA sequence, expression of said DNA sequence encoding said desired product being under the control of said regulatory DNA sequence; (2) transforming said ligated DNA sequence into a Bacillus cell, preferably a B. subtilis ; (3) prior to or after steps (1) and (2), introducing into said bacterial cell an enhancing DNA sequence capable of effecting enhanced expression of said gene encoding said desired product, said enhancing DNA sequence comprising a first and a second sequence, said second sequence being a Bacillus sequence which is not a portion of a sac Q sequence, said first sequence comprising a portion of a sac Q DNA sequence which, when combined with said second sequence is effective to cause said enhancing, said first and second sequences together comprising less than the entire sac Q sequence; (4) culturing said Bacillus cell in a culture medium, and (5) recovering said desired product from said Bacillus cell or culture medium. In further alternative aspects of this invention, we provide a vector comprising a hybrid DNA sequence capable of enhancing the expression of a protease gene in a Bacillus cell, said hybrid DNA sequence being characterized in including a first sequence comprising the sac Q DNA sequence said first sequence by itself not being capable of said enhancing, and a second Bacillus DNA sequence which is not a portion of a sac Q sequence; a vector comprising a hybrid DNA sequence capable of enhancing the expression of a protease gene in a Bacillus cell, said hybrid DNA sequence being characterized in including a first sequence comprising a portion of a sac Q DNA sequence and a second sequence adjacent and downstream from said first sequence, the second sequence comprising and a Bacillus cell transformed with any one of the vectors mentioned above. Thus it will be seen that this invention allows enhanced expression of desired genes in bacteria such as B. subtilis in a simple, inexpensive manner which does not require modifications in the fermentation conditions of the bacteria, and which does not affect the properties of the desired end-products. Other features and advantages will become apparent from the following description of preferred embodiments. The drawings will first briefly be described. In the drawings: Fig. 1 is a diagrammatic representation of the region of the Bacillus amyloliquefaciens chromosome containing an enhancing DNA sequence, termed the Apro DNA sequence; Fig. 2 (a) is the nucleotide sequence of Apro; Fig. 2(b) shows its left end; Fig. 3(a) is the nucleotide sequence of another enhancing DNA sequence, termed the Apro* sequence; Fig. 3(b) shows its left end; Figs. 4(a) and 4(b) are illustrations of the construction of pAS15, a plasmid in which a fusion of two structural genes (alpha-amylase and APIII, described below) is under the transcriptional control of the B. subtilis subtilisin promoter; Fig. 5 is an illustration of the construction of pAL2, a plasmid containing Apro* under the transcriptional control of a strong sporulation promoter, the spo VG promoter; and Fig. 6 is an illustration of pAL3, a derivative of pAL2 from which E. coli sequences have been excised. Structure of Apro and Apro* Figs. 1-3 relate to two particular enhancing DNA sequences of the invention, designated Apro and Apro*. Apro is made up entirely of chromosomal B . amyloliquefaciens DNA, i.e., it is in the second class of enhancing DNA sequence, above. Apro*, containing B . amyloliquefaciens DNA and B . subtilis DNA, is in the first class, above. Referring to Fig. 1, the lower portion of the Figure represents a portion of the chromosome of B . amyloliquefaciens . Restriction enzyme sites are shown as Bcl for Bcl I, Clal for Cla I and RV for Eco RV. Figure 1 also shows the structure of three inserted DNA sequences, Apro, Bpro, and Dpro, which are carried on the plasmids pCL1, pCL2, and pCL4, respectively. A, B, and D represent the approximate positions of Sau 3A restriction sites at the ends of the inserts Apro, Bpro and Dpro, respectively. Approximate sizes, in kilobase pairs, are shown on the lower line. Referring to Figs. 2(a) and 3(a), the nucleotide sequences of the Apro and Apro* enhancing DNA sequences are given. These are numbered from the 5' end starting with the G base of the Sau 3A restriction site at the end of the insert DNA. The first 133 bases of both sequences (reading from left to right) are identical and represent the Sau 3A- Eco RV- Bc lI fragment represented in Fig. 1 as A-Rv-Bcl (reading, in Figure 1, from right to left). The positions of these restriction sites correspond to bases 0, 81, and 128, respectively. The two sequences are also homologous at three base pairs following the Bcl I site. Cloning of Apro A library of B . amyloliquefaciens chromosomal DNA was constructed in B. s ubtilis by partially digesting the chromosomal DNA with Sau 3A and ligating it into a complete Bcl I digest of the positive selection plasmid pBD214. The ligated DNA was used to transform B . subtilis strain BD393, and 6,300 transformed colonies were obtained, selecting for resistance to trimethoprim and chloramphenicol. These colonies were patched onto TBAB plates containing 5 ug/ml chloramphenicol and 1.5% casein. After 12 hours at 37°C. three colonies showed large halos, indicating increased protease production. These colonies were found to contain plasmids, designated pCL1, pCL2, and pCL4, having inserted B . amyloliquefaciens chromosomal DNA which we have designated, respectively, Apro, Bpro, and Dpro. The plasmid DNA of these colonies was isolated and restriction analysis revealed inserts of 750 base pairs, 2.5 kilobase pairs, and 4 kilobase pairs in pCL1, pCL2, and pCL4, respectively. The restriction maps of these three clones do not correspond to that reported for either the neutral or alkaline protease genes from B . amyloliquefaciens , and the DNA sequence of Apro (Fig. 2), determined by standard procedures, did not match the reported sequences of these protease genes. The restriction maps of pCL1, pCL2, and pCL4 are shown in Fig. 1, the inserts being represented as areas between the letters A, B and D, respectively. From these data, and from Southern blot analyses on B . amyloliquefaciens chromosomal DNA, it was determined that all three plasmids contained overlapping fragments of a continuous segment of the B . amyloliquefaciens chromosome. In pCL1 the right hand end (with respect to Fig. 1) of the cloned fragment is defined by a Bcl I site, which is recreated during the cloning process. Protease Production pCL1 was transformed into four competent B . subtilis strains: 1) wild type; 2) neutral-protease-deleted; 3) subtilisin-deleted; and 4) subtilisin and neutral-protease-deleted strains. Protease activity was measured using standard hide-powder azure assays. In wild type strains both alkaline and neutral protease activities were stimulated by pCL1; in the neutral-deleted strain only subtilisin activity was stimulated, in the subtilisin-deleted strain only neutral protease activity was stimulated, and in the double protease deleted strain, no stimulation was observed. The stimulation, when observed, was 5 to 10 fold over wild type levels. Cloning of Apro * A preparation of pCL1 was digested with Bcl I, to give two fragments of approximately 610 base pairs and 5 kilobase pairs, respectively. The DNA was ligated to itself, and the ligated DNA used to transform B. subtilis strain IS75, and the resulting colonies patched onto casein plates as described above. Colonies with twice the halo size of the original Apro clone were selected. Restriction enzyme and Southern analysis demonstrated that they contained a plasmid containing a B. subtilis Bcl I fragment of 170 base pairs; this fragment, which we have shown to be derived from contaminating B. subtilis chromosomal DNA present in the pCL1 preparation, has no demonstrable homology with the 610 base pair Bcl I fragment of Apro. We have called this plasmid pAS20. As shown in Fig. 3, the Apro* sequence contains, upstream from the B. substilis -derived fragment, the 133 base pair Sau 3A- Eco RV- Bcl I B. amyloliquefaciens fragment which is also present in Apro; this fragment of Apro was not removed when pCL1 was digested with Bcl I. Protease assays on the above-described protease deleted and wild type strains of B. subtilis demonstrated that pAS20 stimulated protease production 25 to 50 fold over wild type levels. Cloning of Additional Regulatory Sequences Additional regulatory DNA sequences with similar properties can be isolated from other Bacillus species, using the same techniques employed in obtaining Apro and Apro*. The following example, using B. polymyxa , is illustrative of the method, described above, of isolating an enhancing DNA sequence made up entirely of DNA of one species. A Bgl II digest of B . polymyxa was ligated to pBD214 that had been digested with Bcl I. The resulting DNA was transformed into B . subtilis strain BD393, and clones showing increased protease production on casein plates were selected in the same manner as described above for Apro. From the 1500 colonies picked, two hyperproducers were found. They appear to have identical restriction maps, and have an insert size of about 6kb. The other general enhancing sequence production method, employing a portion of the Apro sequence to generate enhancing DNA sequences containing DNA derived from two species ( B . amyloliquefaciens and one other species) is illustrated by the following example, employing B . polymyxa . pCL1 was digested with Bcl I and re-ligated. This removed the 610 base pair Bcl I fragment while retaining the 133 bp Sau 3A - Eco RV - Bcl I fragment from B . amyloliquefaciens common to both Apro and Apro*. We have called this 133 bp sequence Apro Δ ; the plasmid carrying it, called pAS21, was restricted with Bcl I and then ligated to chromosomal DNA from B . polymyxa which had been completely digested with Bcl I. The resulting DNA was transformed into wild type B . subtilis strain IS75 and screened for protease enhancement. This produced two additional clones which, like pAS20, contained enhancing DNA sequences which were hybrids of DNA from B . amyloliquefaciens and another species. All of these enhancing DNA sequences of both classes act in a similar fashion in that they specifically increase protease production when transformed into strains of B. subtilis containing the subtilisin or neutral protease genes. However, apart from the 133 base pair B. amyloliquefaciens sequence present on some of the enhancing sequences, the enhancing sequences, as tested by Southern blot analysis, do not exhibit homology. Neither Apro nor Apro* sequences hybridize to the enhancing sequences derived wholly from B. polymyxa , or to any region on the B. polymyxa chromosome. Plasmid pAS21 has no enhancing activity of its own, although the Apro Δ B. amyloliquefaciens insert is, as is mentioned above, a preferred component of enhancing sequences. pAS21 (or any other cloning vector carrying the Apro Δ sequence) can therefore be used in the manner described above to isolate enhancing sequences from other Bacillus species. DNA from a desired cell can be digested with Bcl I, or with another enzyme such as Sau 3A, Bam HI, or Bal II, and the resulting DNA ligated into the Bcl I site of pAS21 as described above. The resulting DNA is transformed into wild type B. subtilis and clones exhibiting protease enhancement identified as described above. Any clones so identified will carry DNA that is a hybrid of all or a portion of the original 133 base pair B. amyloliquefaciens DNA (Apro Δ ) and DNA from the other species. Sequencing The sequences of Apro and Apro* are given in Figs. 2(a) and 3(a), respectively. The first 133 base pairs of each are identical and correspond to the Sau 3A- Eco RV- Bcl I fragment of B . amyloliquefaciens DNA (Apro Δ ). The sequences are also homologous at the three base pairs following the Bcl site. The remainder of the DNA sequences show no more than a 12 base pair section of homology to each other. Apro encodes the 46 amino acid product of the sac Q gene of B . amyloliquefaciens which is nearly identical to the B. subtilis sac Q gene as described in Yang et al., id. Apro* encodes a 64 amino acid fusion protein containing the first 36 amino acids of the B . amyloliquefaciens sac Q gene product fused to 28 amino acids encoded by B . subtilis DNA. Construction of an Expression-Secretion Vector The DNA sequences stimulate the production of proteases in B . subtilis . It is possible to place a gene encoding a desired protein downstream from a B . subtilis protease promoter such that it is under the transcriptional control of this promoter. One preferred construction is one in which the desired protein-encoding gene is located within, or downstream from, and in reading frame with, the DNA region encoding the protease signal sequence, which in turn is located downstream from the protease promoter. This construction not only places transcription of the desired gene under the control of the protease promoter, but also effects the secretion of the desired protein, by virtue of the fused protease signal sequence. An enhancing sequence (preferably carried on a multicopy plasmid) can be introduced into the same cells, to increase the level of expression from the protease regulatory DNA, and thus increase the production and secretion of the desired foreign gene product. The promoter for the subtilisin gene of B . subtilis is an appropriate promoter for such a construction since the subtilisin gene contains an Hpa I site in the middle of its signal sequence at which a synthetic linker (e.g., can be inserted. This linker recreates the subtilisin signal sequence and provides a Pst I site to which DNA can be ligated. The putative promoter and signal sequence of the B. subtilis subtilisin gene up to the Hpa I site is with the arrow indicating the Hpa I site. In one such construction, described in detail below, a Bacillus licheniformis structural gene for alpha-amylase, fused to a gene for a desired product known as APIII (discussed below) was inserted at the Pst I site so that the promoter and signal sequence of subtilisin and the structural genes of the alpha-amylase and APIII are in frame. The introduction of an enhancing DNA sequence into a cell containing this fusion was found to enhance the expression of the subtilisin/alpha-amylase/APIII gene fusion. Any other desired gene can be fused in frame to the carboxy-terminal end of the alpha-amylase gene to create a gene fusion encoding a stable hybrid protein, the expression of which is enhanced by the enhancing DNA sequence. The alpha-amylase portion of the hybrid protein will, it is believed, protect the desired protein or peptide portion of the hybrid from degradation; after purification, the alpha-amylase portion can be removed, using standard techniques. Other genes could be used in place of or fused to the gene for alpha-amylase, e.g, genes for medically useful peptides or proteins, e.g., genes for hormones or antiviral proteins, e.g., genes for other naturally-secreted prokaryotic enzymes. Referring to Figs. 4(a) and 4(b), plasmid pAS15, containing the above-mentioned amylase/APIII construction inserted into the Pst I site of the subtilisin gene, was constructed as follows. The amylase/APIII fusion was carried on plasmid pCR33. APIII is a derivative of human natriuretic factor, and is a peptide which can be administered to human patients to control hypertension and regulate serum sodium and potassium levels. Referring to Fig. 4 (a), a portion of the B . subtilis subtilisin gene was cloned on pAS12. An 800 bp Eco Rl- Hpa I fragment (Fragment E in Stahl & Ferrari, 1984, J. Bact. 158: 411-418) containing the subtilisin promoter and signal sequences was isolated from pAS12. The sequence of the putative promoter and the beginning of the signal sequence (up to the Hpa I site) is shown in Stahl & Ferrari (bases 1-177 in Fig. 2 of that paper) and is also shown above. Synthetic linkers (49 + 45 mers, sequence given above), which finished the signal sequence of subtilisin and created a Pst I site at the 3' end, were ligated to the above fragment and the 3.6 kb Eco RI- Pst I backbone from pBR322 containing the Tet R gene. The ligated DNA was then introduced into E . coli cells, strain JM107, and Tet R transformants were selected which were shown to have the correct structure of the finished signal sequence. Plasmid pAS14 was isolated from one of these transformants. Referring to Fig 4 (b), the 850 bp Eco RI- Pst I fragment from pAS14 containing the subtilisin promoter and completed signal sequence was isolated and ligated to a 1.4 kb Pst I- Hind III fragment from pCR33, coding for the amylase-APIII fusion protein, and the 4.3 kb Eco RI- Hind III pBR322 backbone containing the Tet R and Amp R genes. Amp R transformants were obtained by transformation of JM107 cells with the ligated DNA and those found to produce large halos when plated on starch-azure indicator plates were selected. These contained the subtilisin promoter-subtilisin signal sequence-amylase-APIII fusion in the correct orientation. Plasmid pAS15 was isolated from one of these transformants. A chloramphenicol resistance (CAT) gene selectable in B . subtilis was placed on pAS15 to allow chromosomal integration, as follows. pAS15 was partially digested with Sal I and DNA that had been singly cut was isolated. This DNA was ligated to a 1.3 kb Sal I fragment from pEccI (an E . coli plasmid containing the CAT gene) and the ligated DNA was transformed into JM107. Amp R transformants were screened for Tet S and Cm R colonies; plasmid DNA was isolated from a colony (pAS16) that had the correct phenotype. This DNA was then used to integrate the fusion construction into the B . subtilis chromosome. Transformation of B . subtilis resulted in colonies which, when grown on starch-azure plates, produced small halos, indicating secretion of the fusion protein. Competent cells containing pAS16 were made and transformed with pApro*-Tet (Apro* with a Tet R gene) and a control plasmid (p214-Tet). When plated on starch-azure plates, cells containing pApro*-Tet produced a large halo indicating secretion of the amylase-APIII fusion protein. The integration of the CAT gene into the chromosome next to the subtilisin-amylase-APIII DNA construction described above permitted selecting for colonies that grow at higher concentrations (60-90 ug/ml) of chloramphenicol and therefore have an increased copy number of the gene fusion, and thus are capable of increased expression and secretion of the fusion product. Enhancing the Expression of Apro* Referring to Fig. 5, a strong sporulation promoter was placed in front of Apro* as follows. The spo VG promoter (also known as the 0.4 kb gene promoter), a strong sporulation promoter described in Moran et al. (1981) Cell 25 , 783-791, was isolated as a 1.7 kb Eco RI- Xba I fragment from E . coli plasmid pAL1. The sequence of this promoter is given in Moran et al., id. This fragment was ligated with Spe I-cut pApro*-tet. Spe I cuts pApro*-tet approximately 100 bp before the start of the Apro* gene. The ligated DNA was then used to transform the B . subtilis strain having the amylase-APIII fusion chromosomally integrated, as described above (strain GP203). Plasmid DNA from Tet R colonies was isolated, and one plasmid, pAL2, was found to have the spo VG promoter in the right orientation 5' to the Apro* gene. This colony also produced the largest halo on starch-azure indicator plates. Because pAL2 is a large plasmid (11.2 kb) containing a large section of E . coli DNA, a derivative of pAL2 that was smaller and had no E . coli sequences was constructed, as shown in Fig. 6. pAL2 was digested with Eco RI and a 2.3 kb fragment containing the spo VG promoter and the Apro* gene, and a 2.4 kb fragment containing the Tet R gene, were electroeluted from a 0.8% agarose gel. The fragments were then ligated into pBD64 (publicly available; ATCC No. 37104) that had been digested with Eco RI. The ligated DNA was transformed into B . subtilis strain GP203, and plasmid DNA isolated from resulting Tet R colonies. The colonies which had both Eco RI fragments inserted into pBD64, and which therefore had the spo VG-Apro* fusion, had the largest halos on starch-azure plates. Plasmid pAL3 was isolated from one such colony. When cells containing pAL3 were placed on starch-azure plates, halos indicated that this plasmid is stably maintained. pAL3 was found to significantly increase the production of protein from the constructions described herein. Other Embodiments Other embodiments are within the following claims. For example, some enhancing sequences which contain as one component a portion of the above-described AproΔ sequence may contain less than the entire 133 base pairs of AproΔ. The enhancing DNA sequence can be carried on any suitable phage or plasmid vector, which can remain episomal or can integrate into the host cell chromosome. Any suitable Gram-positive host cells can be used, e.g., Bacillus species which are already high producers of commercial proteases; in these host strains, there is no need to transform the host cells with a foreign gene, since the desired gene for the protease is endogenous to the host. Transformation of host cells can be carried out using either protoplasts or competent cells. The sac Q gene from any Bacillus species can be used as the source of all or a portion of the enhancing sequence, e.g., the sac Q gene of B . subtilis and B . licheniformis .

Claims: A vector comprising a Bacillus -derived enhancing DNA sequence capable of enhancing the production of a desired protease in a Bacillus cell, said vector being characterised in including first and second sequences, said second sequence being a Bacillus sequence which is not a portion of a sac Q sequence, said first sequence comprising a portion of a sac Q DNA sequence which when combined with said second sequence causes said enhancing, said first and second sequences together comprising less than the entire sac Q sequence. A vector according to Claim 1, further characterised in that said first sequence comprises the sac Q sequence A vector according to Claim 1 or Claim 2, further characterised in that said second sequence is adjacent and downstream from said first sequence and comprises the sequence A method of making and isolating a DNA sequence capable of enhancing the production of a protease in a Bacillus strain other than a B. amyloliquefaciens strain, said method being characterised in comprising the steps of: (a) providing a cloning vector containing a portion of a Bacillus -derived sac Q DNA sequence. (b) digesting the DNA of a different Bacillus strain to give a plurality of DNA fragments, (c) inserting said fragments into said cloning vectors, (d) transforming bacteria of said bacterial strain with said cloning vectors, (e) assaying protease production in said transformed bacteria, (f) selecting bacteria exhibiting increased protease production, and (g) isolating said enhancing DNA sequence from said bacteria exhibiting increased protease production, said enhancing sequence comprising less than the entire sac Q sequence. A method according to Claim 4, further characterised in that the cloning vector provided contains a fragment of the B. amyloliquefaciens sequence A vector according to any of Claims 1, 2 or 3, further characterised in that said enhancing DNA sequence is under the transcriptional control of a strong promoter. A vector according to Claim 6, further characterised in that said strong promoter is a B. subtilis sporulation promoter, preferably the spo VG promoter. A Bacillus cell characterised in that it is transformed with a gene encoding a desired product and with a Bacillus -derived enhancing DNA sequence capable of enhancing the production of said desired product in said Bacillus cell, in that said enhancing DNA sequence is capable of enhancing the production of an endogenous protease in a Bacillus cell, and in that said enhancing DNA sequence comprises a first and a second sequence, said second sequence being a Bacillus sequence which is not a portion of a sac Q sequence, said first sequence comprising a portion of a sac Q DNA sequence which, when combined with said second sequence causes said enhancing, said first and second sequences together comprising less than the entire sac Q sequence. A Bacillus cell according to Claim 8, further characterised in that said first sequence comprises a fragment of the B. amyloliquefaciens DNA sequence A Bacillus cell according to Claims 8 or 9, further characterised in that said second DNA sequence is derived from or substantially identical to a DNA sequence of a Bacillus cell of a strain other than B. amyloliquefaciens . A Bacillus cell according to any of Claims 8, 9 or 10, further characterised in that adjacent and downstream from said first sequence is the second sequence A Bacillus cell according to any of Claims 8 to 11, further characterised in that expression of the gene encoding said desired product is under the control of regulatory DNA of a protease-encoding gene of a Bacillus cell. A Bacillus cell according to Claim 12, further characterised in that said regulatory DNA includes a DNA region encoding the signal sequence of said protease and the gene encoding said desired product is located within or downstream from said DNA region encoding said signal sequence of said protease. A Bacillus cell according to any of Claims 9 to 13, further characterised in that said Bacillus cell is a strain of: Bacillus subtilis , B. licheniformis , B. acidocaldarius , B. polymyxa , B. stearothermophilus , B. thermoproteolyticus , B. coagulans , B. thuringiensis , B. megaterium , B. cereus , B. natto , or B. amyloliquefaciens ; and in that said second sequence is derived from or substantially identical to a DNA fragment of a Bacillus cell of a strain of any of Bacillus subtilis , B. licheniformis , B. acidocaldarius , B. polymyxa , B. stearothermophilus , B. thermoproteolyticus , B. coagulans , B. thuringiensis , B. megaterium , B. cereus , or B. natto . A Bacillus cell according to any of Claims 8 to 14, further characterised in that said desired product is a protease or an amylase, preferably B. subtilis subtilisin. A Bacillus according to any of Claims 8 to 15, further characterised in that said enhancing DNA is carried on a multicopy plasmid. A Bacillus cell according to any of Claims 8 to 15, further characterised in that said enhancing DNA is integrated into the chromosome of said Bacillus cell. A Bacillus cell according to any of Claims 8 to 17, further characterised in that said product-encoding DNA is fused to the end of a Bacillus gene encoding the carboxy terminal of alpha-amylase. A method for producing a desired product, said method being characterised in comprising the steps of: (1) ligating a DNA sequence encoding said desired product to a DNA sequence including a regulatory DNA sequence which is substantially identical to a regulatory DNA sequence which regulates the expression of a DNA sequence which encodes a protease in a Bacillus species, preferably B. subtilis , to form a ligated DNA sequence, expression of said DNA sequence encoding said desired product being under the control of said regulatory DNA sequence; (2) transforming said ligated DNA sequence into a Bacillus cell, preferably a B. subtilis ; (3) prior to or after steps (1) and (2), introducing into said bacterial cell an enhancing DNA sequence capable of effecting enhanced expression of said gene encoding said desired product, said enhancing DNA sequence comprising a first and a second sequence, said second sequence being a Bacillus sequence which is not a portion of a sac Q sequence, said first sequence comprising a portion of a sac Q DNA sequence which, when combined with said second sequence is effective to cause said enhancing, said first and second sequences together comprising less than the entire sac Q sequence; (4) culturing said Bacillus cell in a culture medium, and (5) recovering said desired product from said Bacillus cell or culture medium. A method according to Claim 19, further characterised in that said first sequence comprises a fragment of the B. amyloliquefaciens DNA sequence A method according to Claim 19 or Claim 20, further characterised in that said second sequence is adjacent and downstream from said first sequence and comprises the sequence A method according to any of Claims 19, 20 or 21, further characterised in that said ligated DNA sequence is carried on a first plasmid and said enhancing DNA sequence is carried on a second plasmid. A method according to any of Claims 19, 20 or 21, further characterised in that said ligated DNA sequence is integrated into the chromosome of said bacterial cell. A method according to any of Claims 19 to 23, further characterised in that said regulatory DNA sequence includes a promoter sequence and a sequence encoding a signal sequence of said protease, said signal sequence effecting the secretion of said desired product. A vector comprising a hybrid DNA sequence capable of enhancing the expression of a protease gene in a Bacillus cell, said hybrid DNA sequence being characterised in including a first sequence comprising the sac Q DNA sequence said first sequence by itself not being capable of said enhancing, and a second Bacillus DNA sequence which is not a portion of a sac Q sequence. A vector comprising a hybrid DNA sequence capable of enhancing the expression of a protease gene in a Bacillus cell, said hybrid DNA sequence being characterised in including a first sequence comprising a portion of a sac Q DNA sequence and a second sequence adjacent and downstream from said first sequence, the second sequence comprising A Bacillus cell transformed with a vector according to any of Claims 1 to 7, 25 or 26.

Inventors: LEE, ROSALIND C., PERO, JANICE, SLOMA, ALAN
Applicants: OMNIGENE INC
Application year: 1986
Main classification: C12N15
IPC codes: C12N9, C12N15, C07K14